EDSA$5.93
Chart
Performance
Key Stats
AI EDSA Summary
Powered by LiveAICalendar
June 2019
10
Next Dividend Date
August 2025
7
Next Earnings Date
H: $
A: $
L: $
Profile
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Seasonals
Price Target
10.33 USD
The 39 analysts offering 1 year price forecasts for EDSA have a max estimate of 17.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Owns multiple supermalls (SM Megamall, SM North EDSA, SM Mall of Asia (accessible via EDSA)) and residential developments directly along or immediately accessible from EDSA, benefiting significantly from its traffic and location.
Weight: 95
Developed and manages major commercial districts (e.g., Ayala Center, Trinoma) and residential projects directly along EDSA, attracting high foot and vehicle traffic.
Weight: 92
Heavily invested in critical infrastructure projects like Skyway (partially runs above EDSA), NLEX-SLEX Connector, and has interests in transportation and fuel (Petron), all directly impacting or benefiting from EDSA's traffic flow.
Weight: 90
Key player in toll road infrastructure (NLEX, SLEX) that connect to EDSA, and utilities (Meralco, Maynilad) providing essential services to areas along EDSA.